Finally, we demonstrated in vitro and in vivo that TIMP1, one of the genes characterizing the CTCs population, promotes proliferation of ovarian cancer cells, suggesting its potential as a therapeutic target. The gene discussed is TIMP1; the disease is ovarian cancer.